Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Friday 9 December

12:00 - 14:00 Registration and lunch
14:00 - 15:15 Session 1: EMPA-KIDNEY - background, trial conduct and
primary outcome
Welcome and introduction Colin Baigent and
Martin Landray
EMPA-KIDNEY design and baseline characteristics Richard Haynes
Primary outcome: overall and by components and subgroups  Will Herrington
15:15 - 15:45  Break
15:45-17:00 Session 2: EMPA-KIDNEY - other outcomes, safety analyses
and meta-analysis
Secondary and tertiary outcomes; safety and laboratory
Richard Haynes
Impact of diabetes on the effects of SGLT-2 inhibitors on kidney
outcomes: a meta-analysis

 Kaitlin Mayne
16:30 - 17:00  Discussion


18:10 Coaches depart from reception for gala dinner

Saturday 10 December

06:30 - 09:00 Registration and breakfast
09:00 - 10:15 Session 3: Diabetes, blood pressure and heart failure - what’s
new from CTSU?
Relationship between blood pressure, kidney function and
chronic kidney disease
Natalie Staplin
Does an aspirin a day keep heart failure away? Michelle Goonasekera
GLP-1 agonists and ASCEND-PLUS Marion Mafham
10:15 - 10:45  Break
10:45 - 12:00 Session 4: Future work
Post-trial follow-up plans and future work Sarah Ng
BI 690517 in patients with CKD: a phase 2 trial Peter Rossing
Study of Heart and Kidney Protection with BI 690517  Parminder Judge
12:00 - 12:30 Discussion
12:30 - 14:00 Lunch and depart